Skip to main content
SpringerLink
Log in

Pharmacometrics in Psychiatric Diseases

  • Chapter
  • First Online:
Applied Pharmacometrics

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 14))

Abstract

Psychiatric disorders may have a huge impact on someone’s personal functioning as well as on the person’s interaction with others. Treatment with psychoactive drugs may be helpful, but there is much room for improvement. To this end, we need much more insight into the disease processes, the fate of psychoactive drugs in the body (particularly the brain), and their associated effects as well as into the sources of intra- and interindividual differences in the pharmacodynamic responses of psychoactive drugs. This can be achieved by quantitative and integrative research approaches on the factors that play a role in the relationship between disease conditions as well as drug dosing and ultimate effects, both at the population and individual level are required. To that end, pharmacometrics is needed, being the science that develops and applies mathematical and statistical methods to quantitatively characterize, understand, and predict drug’s pharmacokinetic, pharmacodynamic, and biomarker outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agarwal N, Port JD, Bazzocchi M, Renshaw PF (2010) Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 255(1):23–41

    PubMed  Google Scholar 

  • Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schüttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65(6):630–639

    CAS  PubMed  Google Scholar 

  • Alhaj H, Wisniewski G, McAllister-Williams RH (2011) The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants. J Psychopharmacol 25(9):1175–1191

    CAS  PubMed  Google Scholar 

  • Alphs L, Fabrizio Benedetti F, Fleischhacker WW, Kane JM (2012) Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 15(7):1003–1014

    PubMed Central  PubMed  Google Scholar 

  • Andreasen NC, Olsen S (1982) Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39(7):789–794

    CAS  PubMed  Google Scholar 

  • Ansseau M, Pitchot W, Moreno AG, Wauthy J, Papart P (2004) Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: effects on sleep REM latency and body temperature. Human Psychopharmacol Clin Exp 8(4):279–283

    Google Scholar 

  • Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ (2003) Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit 25(6):657–664

    CAS  PubMed  Google Scholar 

  • Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S (2009) Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev (3):CD007954

    Google Scholar 

  • Atack JR (2011a) GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem 11(9):1176–1202

    Google Scholar 

  • Atack JR (2011b) GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr Top Med Chem 11(9):1203–1214

    Google Scholar 

  • Baghdady NT, Banik S, Swartz SA, McIntyre RS (2009) Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 26(4):404–424

    PubMed  Google Scholar 

  • Bagli M, Suverkrup R, Quadflieg R, Hoflich G, Kasper S, Moller HJ, Langer M, Barlage U, Rao ML (1999) Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 291:547–554

    CAS  PubMed  Google Scholar 

  • Barbanoj MJ, Riba J, Morte A, Antonijoan RM, Janι F (2002a) Basics of PK-PD using QEEG: acute/repetitive administration, interactions. Focus on anxiolytics with different neurochemical mechanisms as examples. Methods Find Exp Clin Pharmacol 24(Suppl C):67–83

    Google Scholar 

  • Barbanoj MJ, Valle M, Kulisevsky J, Pιrez V, Gambϊs P (2002b) Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. Methods Find Exp Clin Pharmacol 24(Suppl D):139–144

    Google Scholar 

  • Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M (2011) Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 198(1):11–16, sup 1

    PubMed Central  PubMed  Google Scholar 

  • Baskerville TA, Douglas AJ (2008) Interactions between dopamine and oxytocin in the control of sexual behavior. Progress in Brain Research. Advances in vasopressin and oxytocin—from genes to behaviour to disease, Inga DNaR edn. Elsevier: Philadelphia, pp 277–290

    Google Scholar 

  • Baumann P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31(6):444–469

    CAS  PubMed  Google Scholar 

  • Bellani M, Dusi N, Yeh PH, Soares JC, Brambilla P (2011) The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1544–1552

    CAS  PubMed  Google Scholar 

  • Ben Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocrin Rev 22:724–763

    CAS  Google Scholar 

  • Ben Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocrin Rev 29:1–41

    CAS  Google Scholar 

  • Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B (2010) The hypothalamus in schizophrenia research: no longer a wallflower existence. Open Neuroendocrinol J 3:59–67

    CAS  Google Scholar 

  • Bigos KL, Pollock BG, Stankevich BA, Bies RR (2009) Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 6(4):522–543

    PubMed  Google Scholar 

  • Bishop SJ (2007) Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci 11(7):307–316

    PubMed  Google Scholar 

  • Bourin M, Chenu F, Hascoët M (2009) The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Curr Drug Targets 10(11):1052–1060

    CAS  PubMed  Google Scholar 

  • Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA (2009) Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166(1):42–49

    PubMed  Google Scholar 

  • Candy B, Jackson KC, Jones L, Tookman A, King M (2012) Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev 10:CD004596

    PubMed  Google Scholar 

  • Cleton A, Mazee D, Voskuyl RA, Danhof M (1999) Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br J Pharmacol 127(1):227–235

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cloos JM, Ferreira V (2009) Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22(1):90–95

    PubMed  Google Scholar 

  • Correll CU, Kratochvil CJ, March JS (2011) Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72(5):655–670

    PubMed  Google Scholar 

  • Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berlin) 114(4):559–565

    CAS  PubMed  Google Scholar 

  • Czéh B, Di Benedetto B (2013) Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol 23(3):171–185

    PubMed  Google Scholar 

  • Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22:1432–1437

    CAS  PubMed  Google Scholar 

  • Danhof M, de Jongh J, de Lange EC, Della PO, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357–400

    CAS  PubMed  Google Scholar 

  • Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186–191

    CAS  PubMed  Google Scholar 

  • De Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, Bruggeman R, Hoogendijk WJ, Penninx BW (2012) ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. doi:10.1038/tpj.2012.16 (Epub ahead of print)

    Google Scholar 

  • De Lange ECM (2013a) The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. In: Engelhardt B, Stamirovic D, de Lange EC (eds) Fluids and barriers of the CNS, theme issue “Technique and research protocols to study brain barriers in vivo, in vitro and in situ”. Fluids and Barriers CNS 10:12

    Google Scholar 

  • De Lange ECM (2013b) Utility of cerebrospinal fluid in translational neuroscience. J Pharmacokinet Pharmacodyn. (In: Bonate P (ed) Special issue “Translational modeling in neuroscience”). 40(3):315–326

    Google Scholar 

  • De Lange EC, de Boer BA, Breimer DD (1999) Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 36(2–3):211–227

    PubMed  Google Scholar 

  • De Lange EC, Ravenstijn PGM, Groenendaal D, van Steeg TS (2005) Toward the prediction of CNS drug effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7(3):article 54

    Google Scholar 

  • De Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55(1):39–50

    PubMed Central  PubMed  Google Scholar 

  • Delgado MR, Olsson A, Phelps EA (2006) Extending animal models of fear conditioning to humans. Biol Psychol 73(1):39–48

    CAS  PubMed  Google Scholar 

  • Della Paschoa OE, Kruk MR, Danhof M (1998) Phamacokinetic-pharmacodynamic modelling of behavioural responses. Neurosci Biobehav Rev 23(2):229–236

    CAS  PubMed  Google Scholar 

  • Della Pasqua O, Santen GW, Danhof M (2010) The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol Sci 31(4):144–152

    CAS  PubMed  Google Scholar 

  • Détári L, Szentgyörgyi V, Hajnik T, Szénási G, Gacsályi I, Kukorelli T (1999) Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats. Psychopharmacology 142(3):318–326

    PubMed  Google Scholar 

  • DeVane CL, Ware MR, Lydiard RB (1991) Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull 27(4):463–473

    CAS  PubMed  Google Scholar 

  • Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberyé JJ, van Oostenbruggen MF, Massarella J, Segala P, Zell M, Cohen AF (1997) Integrated pharmacokinetics and pharmacodynamics of Ro 48–6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 44(5):477–486

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dolder C, Nelson M, Stump A (2010) Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging 27(8):625–640

    CAS  PubMed  Google Scholar 

  • El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56(8):967–975

    CAS  PubMed  Google Scholar 

  • El-Mallakh RS, Briscoe B (2012) Studies of long-term use of antidepressants: how should the data from them be interpreted? CNS Drugs 26(2):97–109

    CAS  PubMed  Google Scholar 

  • Fahey JM, Pritchard GA, Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ (1998) Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther 285(1):271–276

    CAS  PubMed  Google Scholar 

  • Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP (2012) Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord 26(8):833–843

    PubMed Central  PubMed  Google Scholar 

  • Farahani A, Correll CU (2012) Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73(4):486–496

    CAS  PubMed  Google Scholar 

  • Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF 3rd, Bies RR (2006) Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 61(5):558–569

    CAS  PubMed Central  PubMed  Google Scholar 

  • Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66(5):629–639

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ferrier IN, Johnstone EC, Crow TJ, Rincon-Rodriguez I (1983) Anterior pituitary hormone secretion in chronic schizophrenics. Arch Gen Psychiatry 40(7):755–761

    CAS  PubMed  Google Scholar 

  • Figgitt DP, McClellan KJ (2000) Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60(4):925–954

    CAS  PubMed  Google Scholar 

  • Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22(2 Suppl):12–19

    PubMed  Google Scholar 

  • Fountoulakis KN, Möller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14(3):405–412

    CAS  PubMed  Google Scholar 

  • Fragen RJ (1997) Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Clin Ther 19(3):405–419. (discussion 367–368)

    CAS  PubMed  Google Scholar 

  • Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631

    CAS  PubMed  Google Scholar 

  • Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009a) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84–91

    Google Scholar 

  • Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO (2009b) An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 85(4):409–417

    Google Scholar 

  • Gabrielsson J, Green AR (2009) Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767–774

    CAS  PubMed  Google Scholar 

  • Geldof M, Freijer J, van Beijsterveldt L, Timmerman P, Ahnaou A, Drinkenburg WH, Danhof M (2007) Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci 30(1):45–55

    CAS  PubMed  Google Scholar 

  • Geldof M, Freijer J, van Beijsterveldt L, Danhof M (2008a) Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res 25(4):792–804

    Google Scholar 

  • Geldof M, Freijer JI, Peletier LA, van Beijsterveldt L, Danhof M (2008b) Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. Eur J Pharm Sci 33(3):217–229

    Google Scholar 

  • Geldof M, Freijer JI, van Beijsterveldt L, Langlois X, Danhof M (2008c) Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex. Br J Pharmacol 154(6):1369–1378

    Google Scholar 

  • Ghaemi SN (2008) Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 10(8):957–968

    PubMed  Google Scholar 

  • Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Del Casale A, Tatarelli R, Baldessarini RJ (2009) Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol 24(3):177–190

    CAS  PubMed  Google Scholar 

  • Goldstein JM, Seidman LJ, Makris N, Ahern T, O’Brien LM, Caviness VS Jr, Kennedy DN, Faraone SV, Tsuang MT (2007) Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry 61(8):935–945

    CAS  PubMed  Google Scholar 

  • Goyal N, Gomeni R (2012) Exposure-Response modeling of anti-depressant treatments: the confounding role of placebo effect. J Pharmacokinet Pharmacodyn (Epub ahead of print)

    Google Scholar 

  • Grimsley SR, Jann MW (1992) Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11(11):930–957

    CAS  PubMed  Google Scholar 

  • Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993) An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 8(3):167–172

    CAS  PubMed  Google Scholar 

  • Haenisch B, Bönisch H (2011) Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129(3):352–368

    CAS  PubMed  Google Scholar 

  • Haller J, Alicki M (2012) Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Curr Opin Psychiatry 25(1):59–64

    PubMed  Google Scholar 

  • Haller J, Aliczki M, Gyimesine Pelczer K (2012) Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci Biobehav Rev pii:S0149–S7634(12)00142-X. doi:10.1016/j.neubiorev.2012.09.001. (Epub ahead of print)

    Google Scholar 

  • Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55

    CAS  PubMed  Google Scholar 

  • Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psych 23:56–62

    CAS  Google Scholar 

  • Hedlund JL, Viewig BW (1979) The Hamilton rating scale for depression: a comprehensive review. J Oper Psychiat 10:149–165

    Google Scholar 

  • Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN (2012) Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi:10.1002/14651858.CD004851.pub3

    Google Scholar 

  • Hiemke C, Härtter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85(1):11–28

    CAS  PubMed  Google Scholar 

  • Himmerich H, Wranik DW (2012) Choice of treatment with antidepressants: influencing factors. Curr Pharm Des 18(36):5958–5975

    CAS  PubMed  Google Scholar 

  • Hopewell S, Dutton S, Yu L-M, Chan A-M, Altman DG (2010) The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 340:c723

    Google Scholar 

  • Huh J, Goebert D, Takeshita J, Lu BY, Kang M (2011) Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord. 2011;13(2). pii: PCC.08r00709. doi:10.4088/PCC.08r00709blu

    Google Scholar 

  • Iosifescu DV (2008) Prediction of response to antidepressants: is quantitative EEG (QEEG) an alternative? CNS Neurosci Ther 14(4):263–265

    PubMed  Google Scholar 

  • Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, Pollock BG, Mulsant BH, Bies RR (2012) Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry 20(1):53–60

    PubMed  Google Scholar 

  • Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50(1):73–80

    CAS  PubMed Central  PubMed  Google Scholar 

  • Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT (2002) Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 89(3):428–437

    CAS  PubMed  Google Scholar 

  • Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28(10):2490–2504

    CAS  PubMed Central  PubMed  Google Scholar 

  • Jonker DM, Vermeij DA, Edelbroek PM, Voskuyl RA, Piotrovsky VK, Danhof M (2003) Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. Epilepsia 44(3):329–338

    CAS  PubMed  Google Scholar 

  • Kandel ER, Schwartz JH, Jessell TM (2000) Principles of neural science. McGraw-Hill

    Google Scholar 

  • Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI (2000) Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol 20(3):338–346

    CAS  PubMed  Google Scholar 

  • Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520

    CAS  PubMed  Google Scholar 

  • Karow A, Moritz S, Lambert M, Schoder S, Krausz M (2005) PANSS syndromes and quality of life in schizophrenia. Psychopathology 38:320–326

    CAS  PubMed  Google Scholar 

  • Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R (2009) Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 24(3):119–125

    PubMed  Google Scholar 

  • Kay SR, Flszbein A, Opfer LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 13(2):261–276

    CAS  Google Scholar 

  • Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36(3):504–509

    PubMed Central  PubMed  Google Scholar 

  • Kirsch I (2009) Antidepressants and the placebo response. Epidemiol Psichiatr Soc 18(4):318–322

    PubMed  Google Scholar 

  • Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2006) In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berlin) 188(3):263–272

    CAS  PubMed  Google Scholar 

  • Klomp A, Tremoleda JL, Schrantee A, Gsell W, Reneman L (2012) The use of pharmacological-challenge fMRI in pre-clinical research: application to the 5-HT system. J Vis Exp pii:3956

    Google Scholar 

  • Klotz U (1998) Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 36(11):581–585

    CAS  PubMed  Google Scholar 

  • Kodish I, Rockhill C, Varley C (2011) Pharmacotherapy for anxiety disorders in children and adolescents. Dialogues Clin Neurosci 13(4):439–452

    PubMed Central  PubMed  Google Scholar 

  • Koen N, Stein DJ (2011) Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 13(4):423–437

    PubMed Central  PubMed  Google Scholar 

  • Kokras N, Dalla C, Papadopoulou-Daifoti Z (2011) Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol 7(2):213–226

    PubMed  Google Scholar 

  • Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res 29(7):1932–1948

    CAS  PubMed Central  PubMed  Google Scholar 

  • Krijzer FNCM, Van der Molen R (1987) Classification of psychotropic drugs by rat EEG analysis: the anxiolytic profile in comparison to the antidepressant and neuroleptic profile. Neuropsychobiology 18:51–56

    CAS  PubMed  Google Scholar 

  • Kropf W, Kuschinsky K (1993) Effects of stimulation of dopamine D1 receptors on the cortical EEG in rats: different influences by a blockade of D2 receptors and by an activation of putative dopamine autoreceptors. Neuropharmacology 32:493–500

    CAS  PubMed  Google Scholar 

  • Kruger TH, Hartmann U, Schedlowski M (2005) Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol 23:130–138

    PubMed  Google Scholar 

  • Kuperman S, Johnson B, Arndt S, Lindgren S, Wolraich M (1996) Quantitative EEG differences in a nonclinical sample of children with ADHD and undifferentiated ADD. J Am Acad Child Adolesc Psychiatry 35(8):1009–1017

    CAS  PubMed  Google Scholar 

  • Kurian BT, Greer TL, Trivedi MH (2009) Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 9(7):975–984

    PubMed Central  PubMed  Google Scholar 

  • Lader M (2008) Effectiveness of benzodiazepines: do they work or not? Expert Rev Neurother 8(8):1189–1191

    CAS  PubMed  Google Scholar 

  • Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82(1):21–32

    CAS  PubMed  Google Scholar 

  • Lanni C, Govoni S, Lucchelli A, Boselli C (2009) Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 66(18):2985–3008

    CAS  PubMed  Google Scholar 

  • Lau CE, Wang Y, Ma F (1998) Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam. Eur J Pharmacol 346(2–3):131–144

    CAS  PubMed  Google Scholar 

  • Laurijssens BE, Greenblatt DJ (2002) Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals. J Pharm Pharmacol 54(1):77–86

    CAS  PubMed  Google Scholar 

  • Lenze EJ, Wetherell JL (2011) A lifespan view of anxiety disorders. Dialogues Clin Neurosci 13(4):381–399

    PubMed Central  PubMed  Google Scholar 

  • Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071

    CAS  PubMed  Google Scholar 

  • Lieberman JA (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18(4):251–267

    CAS  PubMed  Google Scholar 

  • Lin JH (2007) Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3(1):81–92

    CAS  PubMed  Google Scholar 

  • Ma G, Friberg LE, Movin-Osswald G, Karlsson MO (2010) Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol 70(6):815–824

    CAS  PubMed Central  PubMed  Google Scholar 

  • Madhusoodanan S, Alexeenko L, Sanders R, Brenner R (2010) Extrapyramidal symptoms associated with antidepressants–a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 22(3):148–156

    PubMed  Google Scholar 

  • Mahmood I, Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36(4):277–287

    CAS  PubMed  Google Scholar 

  • Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61–68

    CAS  PubMed  Google Scholar 

  • Majewska MD (1990) Steroid regulation of the GABAA receptor: ligand binding, chloride transport and behaviour. Ciba Found Symp 153:83–97. (discussion 97–106)

    CAS  PubMed  Google Scholar 

  • Mandema JW, Danhof M (1992) Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 23(3):191–215

    CAS  PubMed  Google Scholar 

  • Mandrioli R, Mercolini L, Raggi MA (2010) Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab 11(9):815–829

    CAS  PubMed  Google Scholar 

  • Mandrioli R, Mercolini L, Saracino MA, Raggi MA (2012) Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 19(12):1846–1863

    CAS  PubMed  Google Scholar 

  • Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC (2005) Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 31(5 Part 1):609–615

    CAS  PubMed  Google Scholar 

  • Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58(12):538–546

    CAS  PubMed  Google Scholar 

  • Matsui-Sakata A, Ohtani H, Sawada Y (2005) Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 20(3):187–199

    CAS  PubMed  Google Scholar 

  • Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46(5):359–388

    CAS  PubMed  Google Scholar 

  • Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225

    CAS  PubMed  Google Scholar 

  • Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104

    CAS  PubMed  Google Scholar 

  • Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H (2012) Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry 37(1):182–187

    CAS  PubMed  Google Scholar 

  • Möller HJ (2009) Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 10(3):180–195

    PubMed  Google Scholar 

  • Movin-Osswald G, Hammarlund-Udenaes M (1995) Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 274:921–927

    CAS  PubMed  Google Scholar 

  • Mucci A, Volpe U, Merlotti E, Bucci P, Galderisi S (2006) Pharmaco-EEG in psychiatry. Clin EEG Neurosci 37(2):81–98

    PubMed  Google Scholar 

  • Mula M (2008) Anticonvulsants—antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 9(8):730–737

    CAS  PubMed  Google Scholar 

  • Muscatello MR, Spina E, Bandelow B, Baldwin DS (2012) Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol 27(3):239–253

    CAS  PubMed  Google Scholar 

  • Nagayama H (1993) Chronopharmacology of psychotropic drugs: circadian rhythms in drug effects and its implications to rhythms in the brain. Pharmacol Ther 59(1):31–54

    CAS  PubMed  Google Scholar 

  • Nejad AB, Ebdrup BH, Glenthøj BY, Siebner HR (2012) Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics. Curr Neuropharmacol 10(3):219–230

    CAS  PubMed Central  PubMed  Google Scholar 

  • Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, Krause D, Seemüller F (2011) Is the PANSS used correctly? a systematic review. BMC Psychiatry 11:113

    PubMed Central  PubMed  Google Scholar 

  • O’Brien FE, Dinan TG, Griffin BT, Cryan JF (2012) Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 165(2):289–312

    PubMed Central  PubMed  Google Scholar 

  • Ohlsen RI, Pilowsky LS (2005) The place of partial agonism in psychiatry. J Psychopharmacol 19(4):408–413

    CAS  PubMed  Google Scholar 

  • Olkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. Handb Exp Pharmacol (182):335–360

    CAS  PubMed  Google Scholar 

  • Ortega I, Perez-Ruixo JJ, Stuyckens K, Piotrovsky V, Vermeulen A (2010) Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. J Clin Pharmacol 50(3):293–310

    CAS  PubMed  Google Scholar 

  • Owen RT (2008) Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. Drugs Today (Barcelona) 44(12):887–893

    CAS  PubMed  Google Scholar 

  • Pigott HE, Leventhal AM, Alter GS, Boren JJ (2010) Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 79(5):267–279

    PubMed  Google Scholar 

  • Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50(7):429–450

    PubMed  Google Scholar 

  • Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Modelling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet 51(4):261–275

    PubMed  Google Scholar 

  • Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004) Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study. Eur Neuropsychopharmacol 14(2):151–155

    CAS  PubMed  Google Scholar 

  • Ploeger BA, van der Graaf PH, Danhof M (2009) Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 24:3–15

    CAS  PubMed  Google Scholar 

  • Price A, Rayner L, Okon-Rocha E, Evans A, Valsraj K, Higginson IJ, Hotopf M (2011) Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 82(8):914–923

    PubMed  Google Scholar 

  • Prichep LS (2005) Use of normative databases and statistical methods in demonstrating clinical utility of QEEG: importance and cautions. Clin EEG Neurosci 36(2):82–87

    PubMed  Google Scholar 

  • Rabinowitz J, Davido O (2008a) The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 34(2):286–291

    Google Scholar 

  • Rabinowitz J, Davidov O (2008b) A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medications. Schizophr Bull 34(6):1145–1150

    Google Scholar 

  • Rabinowitz J, Levine SZ, Barkai O, Davidov O (2009) Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 35(4):775–788

    PubMed Central  PubMed  Google Scholar 

  • Racagni G, Popoli M (2010) The pharmacological properties of antidepressants. Int Clin Psychopharmacol 25(3):117–131

    PubMed  Google Scholar 

  • Riedel M, Strassnig M, Müller N, Zwack P, Möller HJ (2005) How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255(2):143–148

    CAS  PubMed  Google Scholar 

  • Rodgers RJ, Cole JC, Davies A (1994) Anti-anxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav 48(4):959–963

    CAS  PubMed  Google Scholar 

  • Sakai N, Ishizuka M (2009) Impact of rat P450 genetic polymorphism on diazepam metabolism. Expert Opin Drug Metab Toxicol 5(11):1421–1433

    CAS  PubMed  Google Scholar 

  • Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H (2013) Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39(3):564–574

    PubMed Central  PubMed  Google Scholar 

  • Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E (2008) The use of antidepressants in bipolar disorder. J Clin Psychiatry 69(8):1307–1318

    CAS  PubMed  Google Scholar 

  • Samtani MN, Vermeulen A, Stuyckens K (2009) Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 48(9):585–600

    CAS  PubMed  Google Scholar 

  • Schmitt KC, Reith MEA (2010) Regulation of the dopamine transporter. Ann NY Acad Sci 1187:316–340

    CAS  PubMed  Google Scholar 

  • Schosser A, Kasper S (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24(6):277–288

    PubMed  Google Scholar 

  • Seeman P (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4:56–73

    PubMed  Google Scholar 

  • Sehlmeyer C, Dannlowski U, Schöning S, Kugel H, Pyka M, Pfleiderer B, Zwitserlood P, Schiffbauer H, Heindel W, Arolt V, Konrad C (2011) Neural correlates of trait anxiety in fear extinction. Psychol Med 41(4):789–798

    CAS  PubMed  Google Scholar 

  • Sherwin CM, Saldaña SN, Bies RR, Aman MG, Vinks AA (2012) Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit 34(5):535–544

    CAS  PubMed Central  PubMed  Google Scholar 

  • Silverman H (2007) Ethical Issues during the Conduct of Clinical Trials. Proc Am Thoracic Soc 4(2):180–184

    Google Scholar 

  • Spina SP, Ensom MH (2007) Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27(3):389–398

    CAS  PubMed  Google Scholar 

  • Spina E, Santoro V, D’Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206–1227

    CAS  PubMed  Google Scholar 

  • Sramek JJ, Cutler NR (2011) The impact of gender on antidepressants. Curr Top Behav Neurosci 8:231–249

    CAS  PubMed  Google Scholar 

  • Stevens J, Suidgeest E, van der Graaf PH, Danhof M, de Lange EC (2009) A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharm Res 26:1911–1917

    CAS  PubMed Central  PubMed  Google Scholar 

  • Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC (2012) Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39(5):463–477

    CAS  PubMed  Google Scholar 

  • Strawn JR, Sakolsky DJ, Rynn MA (2012) Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc Psychiatr Clin N Am 21(3):527–539

    PubMed  Google Scholar 

  • Suffin SC, Emory WH, Gutierrez N, Arora GS, Schiller MJ, Kling A (2007) A QEEG database method for predicting pharmacotherapeutic outcome in refractory major depressive disorders. J Am Physicians Surg 12(4):104–108

    Google Scholar 

  • Swart EL, Slort PR, Plötz FB (2012) Growing up with midazolam in the neonatal and pediatric intensive care. Curr Drug Metab 13(6):760–766

    CAS  PubMed  Google Scholar 

  • Thaler KJ, Morgan LC, Van Noord M, Gaynes BN, Hansen RA, Lux LJ, Krebs EE, Lohr KN, Gartlehner G (2012) Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 29(6):495–505

    CAS  PubMed  Google Scholar 

  • Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E (2010) Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 49(7):465–478

    CAS  PubMed  Google Scholar 

  • Uchida H, Pollock BG, Bies RR, Mamo DC (2009) Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther 86(4):360–362

    CAS  PubMed  Google Scholar 

  • Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC (2011) Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31:318–325

    CAS  PubMed  Google Scholar 

  • Uzun S, Kozumplik O (2009) Management of side effects of antidepressants—brief review of recommendations from guidelines for treatment of major depressive disorder. Psychiatr Danub 21(1):91–94

    PubMed  Google Scholar 

  • Van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, Heizmann P, Zell M, Cohen AF, Dingemanse J (1997) Integrated pharmacokinetics and pharmacodynamics of Ro 48–8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 44(5):487–493

    PubMed Central  PubMed  Google Scholar 

  • Van Hest A, van Drimmelen M, Olivier B (1992) Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology 107(4):474–479

    PubMed  Google Scholar 

  • Van HL, Schoevers RA, Dekker J (2008) Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harv Rev Psychiatry 16(4):225–234

    PubMed  Google Scholar 

  • Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ (2005) Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 45(5):529–537

    CAS  PubMed  Google Scholar 

  • Vermeulen A, Piotrovsky V, Ludwig EA (2007) Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 34(2):183–206

    CAS  PubMed  Google Scholar 

  • Vgontzas AN, Kales A, Bixler EO (1995) Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 51(4):205–223

    CAS  PubMed  Google Scholar 

  • Vinkers CH, Tijdink JK, Luykx JJ, Vis R (2012) Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics. Ned Tijdschr Geneeskd 155(35):A4900

    PubMed  Google Scholar 

  • Visser SA, Huntjens DR, van der Graaf PH, Peletier LA, Danhof M (2003a) Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats. J Pharmacol Exp Ther 307(2):765–775

    Google Scholar 

  • Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, Danhof M (2003b) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304(1):88–101

    Google Scholar 

  • Von Wolff A, Hölzel LP, Westphal A, Härter M, Kriston L (2013) Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 144(1–2):7–15

    Google Scholar 

  • Walter M, Denier N, Vogel M, Lang UE (2012) Effects of psychoactive substances in schizophrenia—findings of structural and functional neuroimaging. Curr Top Med Chem 12(21):2426–2433

    CAS  PubMed  Google Scholar 

  • Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004) The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7(4):415–419

    CAS  PubMed  Google Scholar 

  • Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay De Vane C (2004a) Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29(3):551–557

    Google Scholar 

  • Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753–760

    CAS  PubMed  Google Scholar 

  • Weihs K, Wert JM (2011) A primary care focus on the treatment of patients with major depressive disorder. Am J Med Sci 342(4):324–330

    PubMed Central  PubMed  Google Scholar 

  • Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR (2010) Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer’s disease trial. J Clin Psychopharmacol 30(6):683–687

    CAS  PubMed  Google Scholar 

  • Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR (2012) Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit 34(2):182–187

    Google Scholar 

  • Whalley HC, Simonotto E, Flett S, Marshall I, Ebmeier KP, Owens DG, Goddard NH, Johnstone EC, Lawrie SM (2004) fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 127(Part 3):478–490

    CAS  PubMed  Google Scholar 

  • Whalley HC, Whyte MC, Johnstone EC, Lawrie SM (2005) Neural correlates of enhanced genetic risk for schizophrenia. Neuroscientist 11(3):238–249

    PubMed  Google Scholar 

  • WHO International Consortium in Psychiatric Epidemiology (2000) Cross-national comparisons of the prevalences and correlates of mental disorders. Bull World Health Organ [online] 78(4):413–426. ISSN 0042–9686

    Google Scholar 

  • Williams PJ (2007) History of phramacometrics. In: Ette EI, Williams PJ (eds) Pharmacometrics. The science of quantitative pharmacology. Whiley, New Jersey

    Google Scholar 

  • Xi G, Hui J, Zhang Z, Liu S, Zhang X, Teng G, Chan KC, Wu EX, Nie B, Shan B, Li L, Reynolds GP (2011) Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by 1H-MRS. PLoS One 6(12):e28686

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB (2012) Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn 39(4):329–341

    CAS  PubMed  Google Scholar 

  • Yuan R, Flockhart DA, Balian JD (1999) Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 39(11):1109–1125

    CAS  PubMed  Google Scholar 

  • Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res 24(11):2031–2039

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Target Site Equilibration Group, Division of Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands

    Elizabeth CM de Lange PhD

Authors
  1. Elizabeth CM de Lange PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth CM de Lange PhD .

Editor information

Editors and Affiliations

  1. University of Florida, Department of Pharmaceutics, Center for Pharmacometrics & Systems Pharmacology, Orlando, Florida, USA

    Stephan Schmidt

  2. University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, Florida, USA

    Hartmut Derendorf

Rights and permissions

Reprints and permissions

Copyright information

© 2014 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

de Lange, E. (2014). Pharmacometrics in Psychiatric Diseases. In: Schmidt, S., Derendorf, H. (eds) Applied Pharmacometrics. AAPS Advances in the Pharmaceutical Sciences Series, vol 14. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1304-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation